Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Financial Officer | March 10, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date March 10, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,883 |
Reported balance
After 2022-03-10 transaction · row 1
1 source rowRow 1 · 2022-03-10 · Sale · Disposed 12,823 · Balance 201,883 F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2022 Filed Mar 14, 2022 20:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 12,823 | $15.55 | $199,334.82 |
DisclosureSEC source: 0001209191-22-018509 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,883 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 8,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 8 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,595 Underlying: Common Stock · 8,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 8,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 7 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 8,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 25,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 6 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,750 Underlying: Common Stock · 25,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 44,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 5 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,300 Underlying: Common Stock · 44,300 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 155,200 | $0.00 Strike: $14.94 | $0.00 |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 4 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,200 Underlying: Common Stock · 155,200 shares Expires 2032-02-29 F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 25,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 1,388 | $12.66 | $17,568.47 |
DisclosureSEC source: 0001209191-22-008849 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,359 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006832 · doc4.xml · derivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on February 1, 2022. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006832 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 2,450 | $22.30 | $54,635.00 |
DisclosureSEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,872 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 12,587 | $21.51 | $270,747.63 |
DisclosureSEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,322 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 33,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037475 · doc4.xml · derivative · entry 4 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 33,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 01:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 100 | $26.44 | $2,644.00 |
DisclosureSEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 5 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,720 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 01:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 27,239 | $25.79 | $702,583.70 |
DisclosureSEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 4 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,820 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.38 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 01:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 800 | $27.33 | $21,862.96 |
DisclosureSEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,059 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.23 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 01:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 29,200 | $26.64 | $777,797.48 |
DisclosureSEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,859 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.23 to $27.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 01:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 30,000 | $26.84 | $805,218.00 |
DisclosureSEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,059 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 8,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 8 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,892 Underlying: Common Stock · 8,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,844 | $23.25 | $66,123.00 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 4 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,059 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 25,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 7 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,500 Underlying: Common Stock · 25,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 33,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 6 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 Underlying: Common Stock · 33,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 116,000 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 5 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 116,000 shares Expires 2031-02-28 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 7,333 | $24.06 | $176,431.98 |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,606 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 25,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007375 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,308 | $21.35 | $27,925.80 |
DisclosureSEC source: 0001209191-21-007375 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,189 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-007375 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064126 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 370 | $4.59 | $1,698.30 |
DisclosureSEC source: 0001209191-20-064126 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,622 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-064126 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 33,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034068 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,189 Underlying: Common Stock · 33,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 9,451 | $1.32 | $12,475.32 |
DisclosureSEC source: 0001209191-20-034068 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,692 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 33,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034068 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 33,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 6 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,189 Underlying: Common Stock · 33,189 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 66,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 5 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,377 Underlying: Common Stock · 66,377 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 116,160 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 4 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,160 Underlying: Common Stock · 116,160 shares Expires 2030-03-01 F4 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 25,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,250 Underlying: Common Stock · 25,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 7,162 | $1.26 | $9,024.12 |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,955 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 25,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016092 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006667 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,308 | $1.28 | $1,674.24 |
DisclosureSEC source: 0001209191-20-006667 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,367 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006667 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061540 · doc4.xml · derivative · entry 3 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 356 | $1.81 | $644.36 |
DisclosureSEC source: 0001209191-19-061540 · doc4.xml · nonDerivative · entry 2 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,800 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:18 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-061540 · doc4.xml · nonDerivative · entry 1 Ruffo Frank · CIK 0001654450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.